NRX Pharmaceuticals
NRXP
34 hedge funds and large institutions have $965K invested in NRX Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 6 closing their positions.
4,100% more call options, than puts
Call options by funds: $42K | Put options by funds: $1K
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
6% more funds holding
Funds holding: 32 → 34 (+2)
0.96% less ownership
Funds ownership: 1.41% → 0.45% (-0.96%)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
80% less capital invested
Capital invested by funds: $4.78M → $965K (-$3.82M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$52.3K |
| 2 |
Renaissance Technologies
New York
|
+$43.3K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$17.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.73M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$234K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$125K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$14.5K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $2.39K | -$6.24K | -1,876 | -67% |
|
|
NA
27
NewEdge Advisors
New Orleans,
Louisiana
| $1.85K | +$1.66K | +500 | +235% |
|
28
Wells Fargo
San Francisco,
California
| $1.4K | +$13 | +4 | +0.7% |
|
29
UBS Group
Zurich,
Switzerland
| $315 | -$516 | -155 | -56% |
|
30
JP Morgan Chase
New York
| $88 | – | – | – |
|
|
HWP
31
Hibernia Wealth Partners
Baton Rouge,
Louisiana
| $65 | +$83 | +25 | New |
|
|
LFG
32
Larson Financial Group
St Louis,
Missouri
| $57 | – | – | – |
|
33
Qube Research & Technologies (QRT)
London,
United Kingdom
| $43 | +$57 | +17 | New |
|
|
AC
34
Armistice Capital
New York
| – | -$2.73M | -563,600 | Closed |
|
|
CH
35
CVI Holdings
Wilmington,
Delaware
| – | -$234K | -48,357 | Closed |
|
|
36
Bank of America
Charlotte,
North Carolina
| – | -$14.5K | -3,000 | Closed |
|
37
Jane Street
New York
| – | -$7.28K | -1,505 | Closed |
|
|
IPW
38
Impact Partnership Wealth
Marietta,
Georgia
| – | -$454 | -94 | Closed |
|
39
Citadel Advisors
Miami,
Florida
| – | -$83 | -25 | Closed |
|
NRXP Hedge Fund Activity: Q3 2023 in Review
34 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q3 2023, worth a combined $965K — down 80% from $4.78M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new NRXP positions and 6 closed out — a net gain of 2 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $52.3K. The largest seller was Armistice Capital, exiting entirely with an estimated $2.73M sold.
- 34 institutional investors held NRX Pharmaceuticals (NRXP) as of Q3 2023, up from 32 in Q2 2023.
- Funds reported $965K of NRX Pharmaceuticals stock for Q3 2023, down 80% quarter-over-quarter.
- 8 funds opened new NRX Pharmaceuticals positions in Q3 2023 and 6 closed out, a net change of +2 holders.
- The largest NRX Pharmaceuticals buyer in Q3 2023 was Millennium Management, an estimated $52.3K added.
- The largest NRX Pharmaceuticals seller in Q3 2023 was Armistice Capital, an estimated $2.73M sold.
Based on aggregated 13F filings for Q3 2023.